Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Different Large Granular Lymphocyte Count Drew Distinguish Characteristics in Large Granular Lymphocytic Leukemia

Ying Yu, Yuxi Li, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Xiong Wenjie, Yuting Yan, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2024-202299

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Xiong Wenjie, Yuting Yan, Ying Yu, Tingyu Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2024-198882

Published: 2024

Journal Articles

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Gang An, Yan Xu, Shuhua Yi, Rui Lyu, Jiaqi Huang, Wensi Li, Yiran Zhang, Liping Lan, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7235.

https://doi.org/10.1182/blood-2024-194774

Published: 2024

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Yuting Yan, Yulan Zhou, Weihao Chen, Jun Wang, Tingyu Wang, Ying Yu, Yujiao Jia, Zhen Yu, Lugui Qiu, Fei Li, Shuhua Yi

Blood (2024) 144 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2024-207323

Published: 2024

Journal Articles

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Yuting Yan, Dandan Shan, Ying Yu, Weihao Chen, Xinyi Zhang, Xiong Wenjie, Tingyu Wang, Mu Hao, Gang An, Lu-Gui Qiu, Zhen Yu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 832.

https://doi.org/10.1182/blood-2024-201941

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Jingjing Yuan, Li Yuxi, Yuting Yan, Xiong Wenjie, Tengteng Yu, Tingyu Wang, Ying Yu, Lugui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2024-206886

Published: 2024

Journal Articles

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Yuting Yan, Yin Liu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Xiong Wenjie, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J. Kipps, Robert Peter Gale, Lu-Gui Qiu, Jifang Zhou, Shuhua Yi

Blood (2024) 144 (Supplement 1): 7820.

https://doi.org/10.1182/blood-2024-204512

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Yujiao Jia, Haoxu Wang, Li Qin, Bingqing Huang, Qi Sun, Huijun Wang, Chengwen Li, Wei Liu, Yan Xu, Shuhua Yi, Lugui Qiu, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2024-209761

Published: 2024

Journal Articles

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Lugui Qiu, Zhuogang Liu, Shuhua Yi, Thanh Nguyen, Wen-Juan Yu, Keshu Zhou, Haiwen Huang, Udomsak Bunworasate, Man Huynh, Hui Zhou, Su-Peng Yeh, Yiqiu Wang, Xiaofeng Liu, Wei Fu

Blood (2024) 144 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2024-193476

Published: 2024

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

NARROW

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Different Large Granular Lymphocyte Count Drew Distinguish Characteristics in Large Granular Lymphocytic Leukemia

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Performance and Challenges of the Lymphgen Classification Algorithm in Real-World Clinical Applications

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only